Pierre-Yves Scarabin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pierre-Yves Scarabin has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Emmanuel Oger
3 shared publications- Emmanuel Oger
G.E.T.B.O. EA-3878 (Groupe d'Etude de la Thrombose de Bretagne Occidentale), Department of Internal Medicine and Chest Diseases, Brest University Hospital, 29609 Brest Cedex, France
3 shared publications Geneviève Plu-Bureau
3 shared publicationsDominique Mottier
2 shared publicationsE. Oger
GETBO, Hôpital de la Cavale Blanche, Brest, France
2 shared publications- Grégoire Le Gal
Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 8L6, Canada
2 shared publications
Latest Publications
- Open Access
- 13 December 2005
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 4 (1) , 71-76
Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism
- 13 December 2005
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 4 (1) , 71-76
Open AccessIndicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism
- 1 July 2005
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 3 (7) , 1535-1537
Genetic variation at the estrogen receptor α locus in relation to venous thromboembolism risk among postmenopausal women
- 1 July 2005
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 3 (7) , 1535-1537
Genetic variation at the estrogen receptor α locus in relation to venous thromboembolism risk among postmenopausal women
- Open Access
- 26 August 2004
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 2 (9) , 1594-1600
Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives
- 26 August 2004
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 2 (9) , 1594-1600
Open AccessImpact of progestagens on activated protein C (APC) resistance among users of oral contraceptives
- Top Cited Papers
- 1 August 2003
- Published by Elsevier in The Lancet
- Vol. 362 (9382) , 428-432
Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk
- 1 August 2003
- Published by Elsevier in The Lancet
- Vol. 362 (9382) , 428-432
Top Cited PapersDifferential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk
- 1 July 2003
- Published by Japan Society of Histochemistry & Cytochemistry in Thrombosis and Haemostasis
- Vol. 90 (1) , 124-31
Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein.
International audienceC-reactive protein (CRP) is one of the main independent predictors of cardiovascular events. Oral post-menopausal estrogen replacement therapy (ERT) increases CRP levels, but the effect of transdermal ERT is not well documented. CRP, interleukine-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels were evaluated in a randomised study of 196 healthy postmenopausal women, who were allocated to receive continuous oral estradiol-1beta, (n=63) or transdermal estradiol-1beta, (n=68) both combined with micronised progesterone, or place-bo (n=65). Oral estrogen increased CRP levels compared with both placebo (p=0.010) and transdermal estrogen (p=0.004) at 6 months. There was no significant effect of transdermal estrogen on CRP levels compared with placebo (p=0.997). No significant difference was found in the median changes for IL-6 and TNF-alpha between the three treatment groups. In conclusion, transdermal estrogen has no significant effect on CRP levels at 6 months, but CRP concentrations increased significantly with oral estrogen although no changes in cytokine levels were detected. The clinical relevance of these effects remains to be determined
- 1 July 2003
- Published by Japan Society of Histochemistry & Cytochemistry in Thrombosis and Haemostasis
- Vol. 90 (1) , 124-31
Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein.
International audienceC-reactive protein (CRP) is one of the main independent predictors of cardiovascular events. Oral post-menopausal estrogen replacement therapy (ERT) increases CRP levels, but the effect of transdermal ERT is not well documented. CRP, interleukine-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels were evaluated in a randomised study of 196 healthy postmenopausal women, who were allocated to receive continuous oral estradiol-1beta, (n=63) or transdermal estradiol-1beta, (n=68) both combined with micronised progesterone, or place-bo (n=65). Oral estrogen increased CRP levels compared with both placebo (p=0.010) and transdermal estrogen (p=0.004) at 6 months. There was no significant effect of transdermal estrogen on CRP levels compared with placebo (p=0.997). No significant difference was found in the median changes for IL-6 and TNF-alpha between the three treatment groups. In conclusion, transdermal estrogen has no significant effect on CRP levels at 6 months, but CRP concentrations increased significantly with oral estrogen although no changes in cytokine levels were detected. The clinical relevance of these effects remains to be determined
- 1 April 2003
- Vol. 88 (4) , 465-9
High plasma concentration of factor VIII coagulant is also a risk factor for venous thromboembolism in the elderly.
A high level of coagulant factor VIII is a well known risk factor for venous thromboembolism, but most studies have enrolled patients under 70 years old. This study aimed to test the hypothesis that an association also exists in the elderly. This hospital-based case-referent study took place at the Department of Internal Medicine and Chest Diseases, University Hospital, Brest, France. We enrolled 161 patients with a first episode of venous thrombosis and 239 subjects, referred for a clinical suspicion of venous thromboembolism which was subsequently ruled out. Factor VIII coagulant activity and plasma fibrinogen concentration were measured. High factor VIII coagulant activity was significantly associated with venous thromboembolism, irrespective of the age group. Patients over 70 years with factor VIII coagulant activity above 225% had a 2.4-fold increased risk of venous thromboembolism compared to those patients with levels below 130% (age- and fibrinogen-adjusted odds ratio: 2.6, 95% CI 1.1 to 6.1). Our results show that high levels of factor VIII coagulant, a determinant of venous thrombosis in adulthood, is also a risk factor in the elderly.
- 1 April 2003
- Vol. 88 (4) , 465-9
High plasma concentration of factor VIII coagulant is also a risk factor for venous thromboembolism in the elderly.
A high level of coagulant factor VIII is a well known risk factor for venous thromboembolism, but most studies have enrolled patients under 70 years old. This study aimed to test the hypothesis that an association also exists in the elderly. This hospital-based case-referent study took place at the Department of Internal Medicine and Chest Diseases, University Hospital, Brest, France. We enrolled 161 patients with a first episode of venous thrombosis and 239 subjects, referred for a clinical suspicion of venous thromboembolism which was subsequently ruled out. Factor VIII coagulant activity and plasma fibrinogen concentration were measured. High factor VIII coagulant activity was significantly associated with venous thromboembolism, irrespective of the age group. Patients over 70 years with factor VIII coagulant activity above 225% had a 2.4-fold increased risk of venous thromboembolism compared to those patients with levels below 130% (age- and fibrinogen-adjusted odds ratio: 2.6, 95% CI 1.1 to 6.1). Our results show that high levels of factor VIII coagulant, a determinant of venous thrombosis in adulthood, is also a risk factor in the elderly.
- 1 January 2003
- Published by Elsevier in Atherosclerosis
- Vol. 166 (1) , 103-109
Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study
- 1 January 2003
- Published by Elsevier in Atherosclerosis
- Vol. 166 (1) , 103-109
Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study
- 1 October 2002
- Published by Japan Society of Histochemistry & Cytochemistry in Thrombosis and Haemostasis
- Vol. 88 (4) , 587-91
Is APC resistance a risk factor for venous thromboembolism in patients over 70 years?
International audienceActivated protein C (APC) resistance is the most common risk factor for venous thromboembolism (VTE). Previous studies mostly analysed patients under 70 years and reported a four- to sevenfold increased risk. This case-control study included consecutive patients referred for a clinical suspicion VTE to our medical unit: 621 patients with a well-documented diagnosis (cases) and 406 patients for which the diagnosis was ruled out and who had no personal history of VTE (controls). APC resistance related to factor V Leiden was defined by either a positive DNA analysis or a positive STA(R) Staclot APC-R assay. Under 70 years, APC resistance was associated with a threefold increased risk of VTE (odds ratio 3.2, 95% CI, 1.7 to 6.0), whereas in patients over 70 years, it appeared to be no longer a strong risk factor (odds ratio 0.8, 95% CI, 0.4 to 1.7). Age appeared as an effect-measure modifier with a significant interaction (p = 0.005). Our data suggest that APC resistance is not a risk factor for VTE in elderly
- 1 October 2002
- Published by Japan Society of Histochemistry & Cytochemistry in Thrombosis and Haemostasis
- Vol. 88 (4) , 587-91
Is APC resistance a risk factor for venous thromboembolism in patients over 70 years?
International audienceActivated protein C (APC) resistance is the most common risk factor for venous thromboembolism (VTE). Previous studies mostly analysed patients under 70 years and reported a four- to sevenfold increased risk. This case-control study included consecutive patients referred for a clinical suspicion VTE to our medical unit: 621 patients with a well-documented diagnosis (cases) and 406 patients for which the diagnosis was ruled out and who had no personal history of VTE (controls). APC resistance related to factor V Leiden was defined by either a positive DNA analysis or a positive STA(R) Staclot APC-R assay. Under 70 years, APC resistance was associated with a threefold increased risk of VTE (odds ratio 3.2, 95% CI, 1.7 to 6.0), whereas in patients over 70 years, it appeared to be no longer a strong risk factor (odds ratio 0.8, 95% CI, 0.4 to 1.7). Age appeared as an effect-measure modifier with a significant interaction (p = 0.005). Our data suggest that APC resistance is not a risk factor for VTE in elderly
- 1 May 2001
- Published by Elsevier in Thrombosis Research
- Vol. 102 (4) , 285-293
Haemostasis in Relation to Dietary Fat as Estimated by Erythrocyte Fatty Acid Composition: The Prime Study
- 1 May 2001
- Published by Elsevier in Thrombosis Research
- Vol. 102 (4) , 285-293
Haemostasis in Relation to Dietary Fat as Estimated by Erythrocyte Fatty Acid Composition: The Prime Study
- 1 January 2001
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 86 (08) , 712-713
The Effects of Transdermal and Oral Estrogen/Progesterone Regimens on Free and Total Protein S in Postmenopausal Women
- 1 January 2001
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 86 (08) , 712-713
The Effects of Transdermal and Oral Estrogen/Progesterone Regimens on Free and Total Protein S in Postmenopausal Women